Edition:
United Kingdom

People: Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

5.52USD
18 Apr 2019
Change (% chg)

$0.33 (+6.36%)
Prev Close
$5.19
Open
$5.20
Day's High
$5.55
Day's Low
$5.04
Volume
194,297
Avg. Vol
186,149
52-wk High
$21.31
52-wk Low
$5.04

Shanler, Stuart 

Mr. Stuart Shanler, M.D., is Chief Scientific Officer since July 2012. Since January 2014, Dr. Shanler has served part-time as a medical and clinical development consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Between July 2011 and July 2012, Dr. Shanler served as a consultant to a number of pharmaceutical companies. Dr. Shanler co-invented a topical rosacea drug for, and co-founded and served as Chief Scientific Officer of, Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his M.D. degree from Albany Medical College of Union University and received B.S. degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, USD 380,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 154,078
Fiscal Year Total, USD 534,078

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --